Patient global assessment is elevated by up to 5 of 10 units in patients with inflammatory arthritis who screen positive for fibromyalgia (by FAST4) and/or depression (by MDS2) on a single multidimensional health assessment questionnaire (MDHAQ)
Authors' conclusion
Median 0-10 PATGL varied from 2-3/10 to 5.5-8/10, according to negative vs positive screening for FM and/or depression on a single MDHAQ for busy clinical settings.
Study context
- Population
- Patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) in routine care in Barcelona, Chicago and Sydney completing a 2-page MDHAQ393 RA and 175 SpA
- Participants
- 305 / 71 / 50 / 92
- Exposure
- FAST4+ vs FAST4- and/or MDS2+ vs MDS2- patients
- FAST4-,MDS2-n = 305reference
- FAST4-,MDS2+n = 71
- FAST4+,MDS2-n = 50
- FAST4+,MDS2+n = 92
- Outcome
- PATGL (0-10) by FAST4 and/or MDS2 screening status
Methodological detailsmulticentre (Barcelona, Chicago, Sydney), routine care, median regression
- Multicentre (Barcelona, Chicago, Sydney)
- Routine care
- Median regression
Main finding
As reported in the abstract
Median PATGL (0-10)
Median PATGL (0-10) FAST4-,MDS2- median 2.0-3.0 · FAST4-,MDS2+ median 5.5-6.0 · FAST4+,MDS2- median 7.0-7.5 · FAST4+,MDS2+ median 7.0-8.0
Proportion of patients
- Median PATGL in all RA and SpA patients
- 5.0
Observational data: associations, not effects.
Further findings
- Proportion of patients with positive FAST4 and/or MDS2 screen
- 41%
Original publication
Patient global assessment is elevated by up to 5 of 10 units in patients with inflammatory arthritis who screen positive for fibromyalgia (by FAST4) and/or depression (by MDS2) on a single MDHAQ. Semin Arthritis Rheum. Published 9 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →